A genetic profiling guideline to support diagnosis and 💕 Molecular Signatures of Lymphoma

The role of molecular profiling in the diagnosis and PubMed

Enhanced clinical assessment of hematologic malignancies

Molecular profiling in lung cancer

Molecular profiling for precision cancer therapies

A genetic profiling guideline to support diagnosis and

Update on the pathologic diagnosis of chronic myelomonocytic

Venetoclax for Patients With Chronic Lymphocytic Leukemia

STAT3 and TP53 mutations associate with poor prognosis in

Chronic lymphocytic leukemia Abstract Europe PMC

Molecular profiling for precision cancer therapies PubMed

Case Report Molecular Profiling Assists in the Diagnosis and

An Overview on Diffuse Large BCell Lymphoma Models Towards

A genetic profiling guideline to support diagnosis and clinical


Clinical and Translational Oncology 1 3 whereas mutations in BCL2 have been linked to veneto-clax resistance [28]. Therefore, choosing between immu-nochemotherapy and targeted therapies for. 6 sept. 2024 · Multiple studies have identified genetic markers that improve diagnostics and prognostication, and next-generation sequencing is becoming an essential tool in the clinical laboratory. This review provides a “next-generation sequencing” guide for lymphomas. It discusses the genetic alterations of the most frequent mature lymphoma. 24 mars 2024 · In this Review, we discuss the current landscape of clinical actionability in precision oncology and the challenges of variant interpretation that have arisen as a result of the rapid and. 14 janv. 2024 · To address these issues, recent guidance from the European Society of Medical Oncology Precision Medicine Working Group recommends that germline-focused analysis should be performed during tumor-only genomic profiling to identify variants with high allele frequencies (> 20–30%) and selected genes of clinical relevance . Referral to genetic subspecialties is also recommended for familial. 17 févr. 2024 · In this study, the current status of the recurrent genetic aberrations observed during diagnosis and/or relapse in HL and the major subtypes of B cell NHL (i.e. diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma) are discussed to shed light on their potential use as noninvasive diagnostic. 9 juin 2024 · We provide an overview of the most recent findings in diffuse large B-cell lymphomas genomics, from the classic functional models used to study tumor biology and the response to experimental treatments using cell lines and mouse models, to the most recent approaches with spheroid/organoid models. 24 mai 2019 · Diffuse large B cell lymphoma (DLBCL) is a highly heterogeneous lymphoid neoplasm with variations in gene expression profiles and genetic alterations, which lead to substantial variations in. The new lymphoma classifications (International Consensus Classification of Mature Lymphoid Neoplasms, and 5th World Health Organization Classification of Lymphoid Neoplasms) include genetics as. 17 févr. 2024 · Recent studies have rapidly identified genomic alterations in B cell lymphomas that may be useful for better subclassification, noninvasive diagnosis, and prediction of response to therapy. The WHO recognizes different lymphoma subsets classified within 2 major categories of B cell lymphoma: Hodgkin's lymphoma (HL) and B cell non. Eur. J. of Cancer Care publishes research on issues affecting the care of cancer patients. Find out how to submit your next open access manuscript to European Journal of Cancer Care. The ASCO 2024 Annual Meeting is now accepting cancer research abstracts. ASCO24 Call for Abstracts is OPEN! Submit your cancer research to the ASCO Annual Meeting. 13 mars 2024 · Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder characterized by features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasm (MPN) [ 1. Chronic myelomonocytic leukemia (CMML) is a rare, heterogeneous myeloid malignancy classified as a myelodysplastic syndromes/myeloproliferative neoplasm (MDS/MPN) overlap syndrome by the World Health Organization (WHO). Its initial presentation can be incidental or associated with myelodysplastic or. 4 avr. 2024 · Diagnostic criteria. For the diagnosis of CMML, the essential methods include peripheral blood tests, bone marrow aspiration and biopsy, chromosomal analysis, and genetic tests. Among them, the morphologic evaluation of peripheral blood and the bone marrow is the basis of CMML diagnosis. 1 nov. 2024 · Molecular profiling is increasingly able to predict a probable primary tumor type for CUP when clinicopathologic workup is inconclusive. Numerous studies have explored the use of various molecular profiling techniques for identification of site/tissue of origin of CUP. These techniques include gene expression profiling utilizing. Studies have explored the use of various molecular profiling techniques to predict prognostic and therapeutic biomarkers, with the goal of improving outcome for patients with CUP. However, discordant results between non-randomized and randomized clinical trials in evaluating tumor-type specific therapies raise uncertainties of the benefits of. 1 nov. 2024 · The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary : Molecular profiling of metastatic cancer of unknown primary Josephine K. Dermawan , Brian P. Rubin Add to Mendeley https://doi.org/10.1053/j.semdp.2024.12.001 Get rights and content Abstract. 1 déc. 2024 · Comprehensive molecular profiling has the potential to contribute to diagnostic categorization and, most importantly, guide CUP therapy through identification of actionable lesions. We here report. 14 janv. 2024 · The implementation of precision medicine through molecular profiling technologies has increasingly been integrated with standard clinicopathological evaluations to enhance diagnosis, prognostication, and prediction of clinical outcomes. Although there have been clear successes in the era of molecular characterization, the utility of. 4 déc. 2024 · The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary : Molecular profiling of metastatic cancer of unknown primary. | Semantic Scholar. DOI: 10.1053/j.semdp.2024.12.001. Corpus ID: 229178760. 14 janv. 2024 · We describe novel molecular characterization strategies beyond tumor DNA sequencing, such as transcriptomics, immunophenotyping, epigenetic profiling, and single-cell analyses. We also review current and potential applications of liquid biopsies to evaluate blood-based biomarkers, such as circulating tumor cells and circulating nucleic acids. 14 janv. 2024 · This review summarizes the current and upcoming approaches to implement precision cancer medicine, highlighting the challenges and potential solutions to facilitate the interpretation and to maximize the clinical utility of molecular profiling results. We describe novel molecular characterization strategies beyond tumor DNA sequencing, such as. 14 janv. 2024 · Cancer precision medicine is defined as “the use of therapeutics that are expected to confer benefit to a subset of patients whose cancer displays specific molecular or cellular features (most commonly genomic changes and changes in gene or protein expression patterns)” [ 1 ]. 30 mars 2024 · Given the heterogeneous nature of the disease, the accurate diagnosis of primary tumor has an even greater role to optimize targeted therapy for patients with CUP. Molecular tumor profiling has been under development over the last decade for predicting the tumor site of origins in patients with CUP (9, 10). Specific gene expression profiles.